Dow Up, Relmada Therapeutics Up

All three major indices gained today.

The NASDAQ gained 308.27 points.

The DOW gained 239.25 points.

The S&P gained 55.97 points.

Technology stocks led the market higher, contributing significantly to the broader rally and pushing the NASDAQ to the strongest performance among the three benchmarks. Strength in large-cap growth companies helped lift overall market sentiment and drew renewed investor interest in the tech sector.

The broader market also participated in the advance, with gains across multiple sectors including financials, industrials, and consumer-related companies. The rise in the S&P 500 suggested that buying activity was not limited to a single segment of the market.

Analysts noted that the coordinated gains across the major indices indicate improving investor confidence, even as markets continue to weigh economic data, corporate outlooks, and expectations surrounding monetary policy.

Investors will continue watching upcoming economic reports and corporate developments later this week for further signals about the economy and financial markets' directions.

All this as Relmada Therapeutics rose 2.72 points to end the day at $7.17. The biotechnology company released encouraging clinical trial results and announced a major capital raise.

The company reported positive 12-month interim Phase 2 data for its experimental bladder cancer treatment NDV-01, showing a 76% complete response rate in patients with non-muscle invasive bladder cancer. The results raised expectations that the therapy could advance into late-stage Phase 3 trials and potentially address a market with limited treatment options.

Relmada also announced an oversubscribed $160 million private placement financing, which will provide additional funding to advance its clinical programs and support operations.

Together, the promising clinical data and strengthened balance sheet drew significant investor attention and helped push the company's shares higher during Monday's trading session.